Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) Equity Average (2016 - 2025)

CorMedix has reported Equity Average over the past 13 years, most recently at $389.7 million for Q4 2025.

  • Quarterly results put Equity Average at $389.7 million for Q4 2025, up 443.66% from a year ago — trailing twelve months through Dec 2025 was $389.7 million (up 443.66% YoY), and the annual figure for FY2025 was $245.0 million, up 216.52%.
  • Equity Average reached $389.7 million in Q4 2025 per CRMD's latest filing, up from $297.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $389.7 million in Q4 2025 and bottomed at $51.5 million in Q2 2023.
  • Median Equity Average over the past 5 years was $65.1 million (2021), compared with a mean of $98.0 million.
  • The largest annual shift saw Equity Average plummeted 54.42% in 2021 before it surged 467.0% in 2025.
  • Over 5 years, Equity Average stood at $66.1 million in 2021, then fell by 15.72% to $55.7 million in 2022, then surged by 37.69% to $76.7 million in 2023, then fell by 6.5% to $71.7 million in 2024, then surged by 443.66% to $389.7 million in 2025.
  • Business Quant data shows Equity Average for CRMD at $389.7 million in Q4 2025, $297.4 million in Q3 2025, and $167.8 million in Q2 2025.